Press

Tryptamine Therapeutics Limited Appoints David Castle to Its Scientific Advisory Board

Aug 2 • 2 min read

Tryptamine Therapeutics Limited announce the appointment of Professor David Castle to its Scientific Advisory Board (`SAB’). Professor Castle is a leading psychiatric scholar who was recently appointed by the Tasmanian Government as Professor of Psychiatry at the University of Tasmania’s Centre for Mental Health Service Innovation, which was launched in partnership with the Tasmanian Department…

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

Aug 1 • 3 min read

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has entered into a $25 million common stock purchase agreement (the “Purchase Agreement”) with White Lion Capital, LLC, (“White Lion”) a California-based institutional investor focused on high-growth, early-stage public companies. Psyence Biomed…

Revitalist Lifestyle and Wellness CEO Kathryn A. Walker to Speak at The AANA Annual Congress on Psychedelics in Anesthesia

Jul 31 • 3 min read

Vancouver, British Columbia–(Newsfile Corp. – July 31, 2024) – Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO) (the “Company”) announces that Kathryn A. Walker, CEO of Revitalist Lifestyle and Wellness Ltd., will be presenting at the American Association of Nurse Anesthesiologists (AANA) Annual Congress. The event will take place from August 2-6,…

Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension

Jul 31 • 3 min read

Toronto, Ontario–(Newsfile Corp. – July 31, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (“AUD”), is pleased to announce that, further to its press releases dated…

Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research

Jul 31 • 4 min read

Vancouver, Canada, July 31, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today concluded its successful participation at the Psychedelic Medicine – Israel 2024 conference. The event took place in Tel Aviv, Israel, bringing together leading…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435